Clinical trials
Observational Breast Neoplasms trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
44 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 22 |
| Completed | 14 |
| Recruiting | 7 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 14 |
| Chang Gung Memorial Hospital | 5 |
| AstraZeneca | 2 |
| Kaohsiung Veterans General Hospital. | 2 |
| Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 2 |
| Taipei Veterans General Hospital, Taiwan | 2 |
| Academia Sinica, Taiwan | 1 |
| Amwise Diagnostics Pte. Ltd. | 1 |
| CellMaxLife | 1 |
| Chen-Pin Chou | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 44 |
| Breast Diseases | 2 |
| Lung Neoplasms | 2 |
| Lymphedema | 2 |
| Neoplasms | 2 |
| Brain Neoplasms | 1 |
| Breast Neoplasms, Male | 1 |
| COVID-19 | 1 |
| Carcinoma, Intraductal, Noninfiltrating | 1 |
| Disease | 1 |
Trials
Showing 1 to 25 of 44. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.